Chinese medicine stocks that won two consecutive boards, and the stock price rose rapidly on November 14

【Pharmaceutical Network Pharmaceutical Stock Market】On October 14, the traditional Chinese medicine sector changed, of which the closing price increase deviation value reached 20% in two consecutive trading days (November 10, November 11), reaching 2 consecutive boards of Longjin Pharmaceutical, and the stock price rose
rapidly on the 14th.
Longjin Pharmaceutical rose rapidly intraday on the 14th, rising more than 2% in 5 minutes, as of 9:35, it was reported at 16.
75 yuan, with a transaction of 357 million yuan and a turnover rate of 5.
49%.

On the news, Longjin Pharmaceutical issued an announcement on abnormal fluctuations in stock trading on November 13, saying that the company's recent operating conditions are normal, there have been no major changes in the internal and external operating environment, and there are currently no major matters
that should be disclosed but not disclosed.
Kunming Qunxing Investment Co.
, Ltd.
, the company's controlling shareholder, reduced its holdings of 2.
95 million shares of the company's shares through centralized bidding transactions during the abnormal fluctuation of stock trading, with an average price of 15.
2 yuan per share, and its concerted actor and actual controller of the company, Fan Xianru, did not buy or sell the company's shares during the period
.
It is understood that Longjin Pharmaceutical has risen 29 times
in the past year.
For the reasons for the change in the stock, the analysis believes that it is mainly affected by three factors, including traditional Chinese medicine, industrial hemp, high-end generic drugs and other conceptual factors
.
Longjin Pharmaceutical is a pharmaceutical company
engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs.
The company's main products are Longjin injection lamp anthocyanin, which is a high-purity traditional Chinese medicine lyophilized powder injection, the product has the effect of activating blood circulation and removing stasis, channeling and relieving pain, used for the treatment of cardiovascular and cerebrovascular diseases, mainly used for the treatment of stroke and its sequelae, coronary heart disease, angina
.
At the same time, the company has increased its capital in Yunnan Muya Agricultural Technology Co.
, Ltd.
(Muya Agriculture) by 15 million yuan and obtained 51% of its equity
.
Muya Agriculture's main business is large-scale cultivation of industrial hemp
.
In addition, the company also introduced external investment to establish Yunnan Longjin Kangyou Biopharmaceutical Company as a high-end chemical generic drug development platform
.
From the perspective of the entire traditional Chinese medicine market, in fact, since the end of September, the entire traditional Chinese medicine sector has begun to rebound, from September 27 to November 10, the traditional Chinese medicine index has risen by more than 30%, and related concept stocks have risen sharply in turn, in addition to Longjin Pharmaceutical, such as Zhongsheng Pharmaceutical won 4 days and 3 boards, and Teyi Pharmaceutical also recorded 3 days and 2 boards
.
From the analysis point of view, behind the active performance of the traditional Chinese medicine sector is the impact of frequent favorable industry policies, coupled with the aging and consumption upgrades, the traditional Chinese medicine market space is huge
.
On the policy side, in recent years, from top-level design to specific measures, from approval and review, talent development, medical insurance payment to service system, the state has issued relevant policies to encourage the development of
traditional Chinese medicine.
The "14th Five-Year Plan for the Development of Traditional Chinese Medicine" released in March this year clarifies the goals and main tasks of the "14th Five-Year Plan" for the development of traditional Chinese medicine, and points out that traditional Chinese medicine has ushered in rare development opportunities in the world's unprecedented changes in a century, and it is urgent to accelerate the revitalization and development of
traditional Chinese medicine.
On October 27, the State Administration of Traditional Chinese Medicine issued the "14th Five-Year Plan for the Development of Chinese Medicine Talents", which clearly stated that by 2025, the number of Chinese medicine personnel will increase to more than 1 million (+21%)
.
Kaiyuan Securities recently said that under a series of favorable policies, the entire industry chain of traditional Chinese medicine, including research and development, planting, medical services, sales, decoction and other links, is expected to continue to benefit, and the bank is optimistic about the long-term development of
the traditional Chinese medicine industry.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.